Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer

Eitemau Tebyg

• A gene signature for selecting benefit from hypoxia modification of radiotherapy for high risk bladder cancer patients
  gan: Yang, L, et al.
  Cyhoeddwyd: (2017)
• A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
  gan: Eustace, A, et al.
  Cyhoeddwyd: (2013)
• Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial
  gan: Eustace, A, et al.
  Cyhoeddwyd: (2013)
• Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
  gan: Eustace, A, et al.
  Cyhoeddwyd: (2013)
• Impact of Hypoxia-Induced miR-210 on Pancreatic Cancer
  gan: Mutian Lian, et al.
  Cyhoeddwyd: (2023-12-01)